nach oben

Erschienen in:

04.11.2019 | Asthma bronchiale | Leitlinie

ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem

verfasst von: Ludger Klimek, Claus Bachert, Oliver Pfaar, Sven Becker, Thomas Bieber, Randolf Brehler, Roland Buhl, Ingrid Casper, Adam Chaker, Wolfgang Czech, Jörg Fischer, Thomas Fuchs, Michael Gerstlauer, Karl Hörmann, Thilo Jakob, Kirsten Jung, Matthias V. Kopp, Vera Mahler, Hans Merk, Norbert Mülleneisen, Katja Nemat, Uta Rabe, Johannes Ring, Joachim Saloga, Wolfgang Schlenter, Carsten Schmidt-Weber, Holger Seyfarth, Annette Sperl, Thomas Spindler, Petra Staubach, Sebastian Strieth, Regina Treudler, Christian Vogelberg, Andrea Wallrafen, Wolfgang Wehrmann, Holger Wrede, Torsten Zuberbier, Anna Bedbrook, Giorgio W. Canonica, Victoria Cardona, Thomas B. Casale, Wienczylawa Czarlewski, Wytske J. Fokkens, Eckard Hamelmann, Peter W. Hellings, Marek Jutel, Désirée Larenas-Linnemann, Joaquim Mullol, Nikolaos G. Papadopoulos, Sanna Toppila-Salmi, Thomas Werfel, Prof. Dr. Jean Bousquet

Erschienen in: Allergo Journal | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die Anzahl der von Allergien betroffenen Patienten nimmt weltweit zu. Hiermit gehen erhebliche Kosten für die Gesundheits- und Sozialsysteme durch allergische Erkrankungen einher. Integrierte Versorgungskonzepte sind erforderlich, die innerhalb der nationalen Gesundheitssysteme eine umfassende Versorgung ermöglichen. Die ARIA-Initiative entwickelt international gültige Leitlinien für allergische Atemwegserkrankungen.

Methoden

ARIA dient der verbesserten Versorgung von Patienten mit Allergien und chronischen Atemwegserkrankungen. In Zusammenarbeit mit anderen internationalen Initiativen, nationalen Fachgesellschaften und Patientenorganisationen im Bereich Allergien und Atemwegserkrankungen wurde eine realitätsnahe, integrative Versorgungsleitlinie („integrated care pathways“, ICPs) für eine digital unterstützte, integrative, individualisierte Behandlung von allergischer Rhinitis (AR) mit komorbidem Asthma entwickelt, die in der vorliegenden Arbeit auf das deutsche Gesundheitssystem übertragen wird.

Ergebnisse

Die vorliegende ICP-Versorgungsleitlinie umfasst wesentliche Bereiche der Versorgung von Patienten mit AR mit und ohne Asthma einschließlich der Sicht von Patienten und weiterer versorgungsnaher Gesundheitsdienstleister.

Diskussion

Eine umfassende ICP-Leitlinie kann die Versorgungsrealität wesentlich besser abbilden als herkömmliche Leitlinienmodelle.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al.; World Health Organization, GA(2)LEN, AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63 Suppl 86:8–160PubMedCrossRef

Canonica GW, Bachert C, Hellings P, Ryan D, Valovirta E, Wickman M et al. Allergen Immunotherapy (AIT): a prototype of Precision Medicine. World Allergy Organ J 2015;8:31PubMedPubMedCentralCrossRef

Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140:950–8PubMedCrossRef

Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol 2017;119:489–511.e41PubMedCrossRef

Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al.; Global Allergy and Asthma European Network, Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466–76PubMedCrossRef

Larenas-Linnemann D, Mayorga-Butrón JL, Sánchez-González A, Ramírez-García A, Medina-Ávalos M, Figueroa-Morales MA et al.; Asociación Nacional de Médicos Generales y Médicos Familiares, Colegio Mexicano de Inmunología Clínica y Alergia, Colegio Mexicano de Pediatras Especialistas en Inmunología y Alergia, Confederación Nacional de Pediatría México, Federación Mexicana de Otorrinolaringología y Cirugía de Cabeza y Cuello, Sociedad Mexicana de Otorrinolaringología y Cirugía de Cabeza y Cuello, Sociedad Mexicana de Pediatría, Sociedad Mexicana de Neumología Pediátrica, Sociedad Mexicana de Neumología y Cirugía de Tórax, Ibero American Agency for Development and Assessment of Health Technologies. [ARIA Mexico 2014. Adaptation of the Clinical Practice Guide ARIA 2010 for Mexico. Methodology ADAPTE]. 2014;61 Suppl 1:S3–S116PubMed

Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013;68:1102–16PubMed

Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child 2015;100:576–82PubMedCrossRef

Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S et al.; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:19–42PubMedCrossRef

10.

Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA et al.; Joint Task Force on Practice, American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1–84PubMedCrossRef

11.

Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282–9.e10PubMedCrossRef

12.

Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105:168–73PubMedCrossRef

13.

Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc 2013;34:301–11PubMedCrossRef

14.

Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg 2015;152:197–206PubMedCrossRef

15.

Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy 2018;8:25PubMedPubMedCentralCrossRef

16.

Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clinical Immunol Pract 2018;6:1726–32.e6CrossRef

17.

Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J et al.; Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459–66PubMedCrossRef

18.

Bousquet J, Hellings PW, Agache I, Amat F, Annesi-Maesano I, Ansotegui IJ et al.; Mobile Airways Sentinel Network (MASK) Study Group. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol 2019;143:864–79PubMedCrossRef

19.

Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E et al.; MASK study group. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45PubMedPubMedCentralCrossRef

20.

Bousquet J, Anto JM, Annesi-Maesano I, Dedeu T, Dupas E, Pépin JL et al. POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clin Transl Allergy 2018;8:36PubMedPubMedCentralCrossRef

21.

Klimek L, Werfel T, Vogelberg C, eds. Weißbuch Allergie in Deutschland. 4. Auflage. Berlin—Heidelberg: Springer 2018

22.

Schmitz R, Kuhnert R, Thamm M. 12-Monats-Prävalenz von Allergien in Deutschland. J Health Monitoring 2017;2:77–82; [URL: https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsJ/FactSheets/JoHM_2017_01_gesundheitliche_lage6.pdf?__blob=publicationFile]

23.

Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. BMJ 1998;316:133–7PubMedPubMedCentralCrossRef

24.

Hujala A, Taskinen H, Rissanen TH. How to support integration to promote care for people with multimorbidity in Europe? In: Richardson E, van Ginneken E, eds. European Observatory Policy Briefs, Policy Brief, No. 26. Copenhagen: European Observatory on Health Systems and Policies 2017

25.

Palmer K, Marengoni A, Forjaz MJ, Jureviciene E, Laatikainen T, Mammarella F et al.; Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Multimorbidity care model: Recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Health Policy 2018;122:4–11PubMedCrossRef

26.

Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A et al.; European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy, WP 10; Global Alliance against Chronic Respiratory Diseases. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014;44:304–23PubMedCrossRef

27.

Bousquet J, Pham-Thi N, Bedbrook A, Agache I, Annesi-Maesano I, Ansotegui I et al. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases. POLLAR (Impact of Air POLLution on Asthma and Rhinitis, member of EIT Health), GARD Research Demonstration Project, Reference Site Network of the European Innovation Partnership on Active and Healthy Ageing in revision 2018. https://doi.org/10.21037/jtd.2019.08.64

28.

Bousquet J, Pham-Thi N, Bedbrook A, Agache I, Annesi-Maesano I, Ansotegui I et al. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases. Part 2: Workshop report. POLLAR (Impact of Air POLLution on Asthma and Rhinitis, member of EIT Health), GARD ResearchDemonstration Project, Reference Site Network of the European Innovation Partnership on Active and Healthy Ageing in revision 2018. https://doi.org/10.21037/jtd.2019.09.38

29.

Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? J Allergy Clin Immunol Pract 2016;4:682–8 e6PubMedCrossRef

30.

Muñoz-Cano R, Ribó P, Araujo G, Giralt E, Sanchez-Lopez J, Valero A. Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort. Clin Transl Allergy 2018;8:23PubMedPubMedCentralCrossRef

31.

Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M et al. Impact of Rhinitis on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract 2018;6:1274–86.e9PubMedCrossRef

32.

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A et al.; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol 2016;138:367–74.e2PubMedCrossRef

33.

Courbis AL, Murray RB, Arnavielhe S, Caimmi D, Bedbrook A, van Eerd M et al. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy 2018;48:1640–53PubMedCrossRef

34.

Briere JB, Bowrin K, Taieb V, Millier A, Toumi M, Coleman C. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. Curr Med Res Opin 2018;34:2125–30PubMedCrossRef

35.

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL et al. Real-World Evidence — What Is It and What Can It Tell Us? N Engl J Med 2016;375:2293–7PubMedCrossRef

36.

United States Department of Health and Human Services — Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Guidance for Industry and Food and Drug Administration Staff. 2017; [URL: https://www.fda.gov/media/99447/download]

37.

Brożek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009;64:669–77PubMedCrossRef

38.

Brożek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011;66:588–95PubMedCrossRef

39.

Brożek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009;64:1109–16PubMedCrossRef

40.

Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res 2016;16:299PubMedPubMedCentralCrossRef

41.

Bousquet J, Devillier P, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy 2018.;73:17631–74

42.

Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:vi, xi–xiv, 1–322CrossRef

43.

Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K et al. Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int 2017;26:16–24PubMedPubMedCentralCrossRef

44.

Horak F, Bruttmann G, Pedrali P, Weeke B, Frølund L, Wolff HH et al. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung 1988;38:124–8PubMed

45.

Kaszuba SM, Baroody FM, deTineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001;161:2581–7PubMedCrossRef

46.

Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D et al. Treatments for Seasonal Allergic Rhinitis. In: Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center, prepared by. Comparative Effectiveness Review, No. 120. Rockville (MD): Agency for Healthcare Research and Quality (US) 2013

47.

United States Department of Health and Human Services — Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Allergic Rhinitis: Developing Drug Products for Treatment. Guidance for Industry. 2018; [URL: https://www.fda.gov/media/71158/download]

48.

United States Department of Health and Human Services — Food and Drug Administration. Draft Guidance for Industry on Allergic Rhinitis: Clinical Development Programs for Drug Products; Availability 2000; [URL: www.federalregister.gov/documents/2000/06/21/00-15632/draft-guidance-for-industry-on-allergic-rhinitis-clinical-development-programs-for-drug-products]

49.

Katial RK, Salapatek AM, Patel P. Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? Allergy Asthma Proc 2009;30:595–604PubMedCrossRef

50.

Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bønløkke JH et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future — an EAACI Position Paper. Allergy 2017;72:1035–42PubMedCrossRef

51.

Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 2007;21:499–503PubMedCrossRef

52.

Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 2007;137:918–24PubMedCrossRef

53.

Salapatek AM, Lee J, Patel D, D’Angelo P, Liu J, Zimmerer RO Jr et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc 2011;32:221–9PubMedCrossRef

54.

Horak F, Zieglmayer UP, Zieglmayer R, Kavina A, Marschall K, Munzel U et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 2006;22:151–7PubMedCrossRef

55.

Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R et al. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy 2015;45:1346–55PubMedCrossRef

56.

Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin 2008;24:1833–40PubMedCrossRef

57.

Sleurs K, Seys SF, Bousquet J, Fokkens WJ, Gorris S, Pugin B et al. Mobile health tools for the management of chronic respiratory diseases. Allergy 2019;74:1292–306PubMed

58.

Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy 2016;6:47PubMedPubMedCentralCrossRef

59.

Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S et al.; MASK study group. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol 2019;144:135–43.e6PubMedCrossRef

60.

Menditto E, Guerriero F, Orlando V, Crola C, Di Somma C, Illario M et al. Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population. J Aging Res 2015;2015:682503PubMedPubMedCentralCrossRef

61.

Caimmi D, Baiz N, Tanno LK, Demoly P, Arnavielhe S, Murray R et al.; MASK Study Group. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clin Exp Allergy 2017;47:1526–33PubMedCrossRef

62.

Bonini M. Electronic health (e-Health): emerging role in asthma. Curr Opin Pulm Med 2017;23:21–6PubMedCrossRef

63.

Bousquet J, Arnavielhe S, Bedbrook A, Fonseca J, Morais Almeida M, Todo Bom A et al.; MASK study group. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy 2018;73:505–10PubMedCrossRef

64.

Bousquet J, Caimmi DP, Bedbrook A, Bewick M, Hellings PW, Devillier P et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. Allergy 2017;72:857–65PubMedCrossRef

65.

Bousquet J, Devillier P, Anto JM, Bewick M, Haahtela T, Arnavielhe S et al.; MACVIA working group. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy 2018;73:1622–31PubMedCrossRef

66.

Bousquet J, VandenPlas O, Bewick M, Arnavielhe S, Bedbrook A, Murray R et al. The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. J Investig Allergol Clin Immunol 2018;28:42–4PubMedCrossRef

67.

Pizzulli A, Perna S, Florack J, Pizzulli A, Giordani P, Tripodi S et al. The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2014;44:1246–54PubMedCrossRef

68.

Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy 2015;5:39PubMedPubMedCentralCrossRef

69.

Bousquet J, Murray R, Price D, Somekh D, Münter L, Phillips J et al. The allergic allergist behaves like a patient. Ann Allergy Asthma Immunol 2018;121:741–2PubMedCrossRef

70.

Patel P, Patel D, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ear Nose Throat J 2008;87:340–53PubMedCrossRef

71.

Bonertz A, Roberts G, Slater JE, Bridgewater J, Rabin RL, Hoefnagel M et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy 2018;73:816–26PubMedCrossRef

72.

Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol 2017;28:728–45PubMedCrossRef

73.

Muraro A, Roberts G, Halken S, Agache I, Angier E, Fernandez-Rivas M et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018;73:739–43PubMedCrossRef

74.

Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282–319PubMedPubMedCentralCrossRef

75.

Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2017;73:765–98PubMedCrossRef

76.

Ryan D, Gerth van Wijk R, Angier E, Kristiansen M, Zaman H, Sheikh A et al. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy 2018;73:827–36PubMedCrossRef

77.

Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy 2018;73:165–77PubMedCrossRef

78.

Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437–52PubMedCrossRef

79.

Greiner W, Graf von der Schulenburg JM, Gillissen A. Kosten und Nutzen der Hyposensibilisierung bei allergischem Asthma und Rhinitis. Gesundh ökon Qual manag 2003;8:179–86CrossRef

80.

Klimek L, Chaker AM, Mösges R. [Costs of allergic diseases and saving potential by allergen-specific immunotherapy: A personal assessment]. HNO 2017;65:801–10PubMedCrossRef

81.

Reinhold T, Brüggenjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. Allergo J Int 2017;26:7–15PubMedCrossRef

82.

Larenas-Linnemann DES, Antolín-Amérigo D, Parisi C, Nakonechna A, Luna-Pech JA, Wedi B et al. National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II. Allergy 2018;73:664–72PubMedCrossRef

83.

Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW et al.; European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69:854–67PubMedCrossRef

84.

Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG et al.; ARIA Working Group. 2019 ARIA Care pathways for allergen immunotherapy. Allergy 2019; doi: https://doi.org/10.1111/all.13805

85.

Bonertz A, Roberts GC, Hoefnagel M, Timon M, Slater JE, Rabin RL et al. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy 2018;73:64–76PubMedCrossRef

86.

European Medicines Agency — Committee for Medical Products for Human Use (CHMP). Guideline on Allergen Products: Production and Quality Issues (EMEA/CHMP/BWP/304831/2007). 2008; [URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-allergen-products-production-quality-issues_en.pdf]

87.

Bachert C, Larché M, Bonini S, Canonica GW, Kündig T, Larenas-Linnemann D et al. Allergen immunotherapy on the way to product-based evaluation — a WAO statement. World Allergy Organ J 2015;8:29PubMedPubMedCentralCrossRef

88.

Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 2016;9:33PubMedPubMedCentralCrossRef

89.

European Medicines Agency — Committee for Medical Products for Human Use (CHMP). Guideline on the Clinical Development of Products for Specific immunotherapy for the Treatment of Allergic Diseases (CHMP/EWP/18504/2006). 2008; [URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf]

90.

Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401–5PubMedCrossRef

91.

Richtlinie 89/342/EWG des Rates vom 3. Mai 1989 zur Erweiterung des Anwendungsbereichs der Richtlinien 65/65/EWG und 75/319/EWG und zur Festlegung zusätzlicher Vorschriften für aus Impfstoffen, Toxinen oder Seren und Allergenen bestehende immunologische Arzneimittel. Amtsbl EG 1989;L 142:14–15. [URL: https://eur-lex.europa.eu/legal-content/DE/TXT/PDF/?uri=CELEX:31989L0342&from=DE]

92.

Richtlinie 2001/83/EG des Europäischen Parlaments und des Rates vom 6. November 2001 zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel. Amtsbl EG 2001;L 311:67–128. [URL: https://eur-lex.europa.eu/legal-content/DE/TXT/PDF/?uri=CELEX:32001L0083&from=DE]

93.

Mahler V, Weber G, Vieths S. Regulation von Allergenprodukten in Deutschland und behördliche Überwachung. In: Klimek L, Vogelberg C, eds. Weißbuch Allergologie. 4. Auflage. Heidelberg—Berlin: Springer 2018; pp. 380–90

94.

Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz — AMG). Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), zuletzt durch Artikel 1 des Gesetzes vom 18. Juli 2017 (BGBl. I S. 2757) geändert. 2017; [URL: https://www.pei.de/SharedDocs/Downloads/gesetze/arzneimittelgesetz.pdf?__blob=publicationFile&v=31]

95.

Nelson HS, Iklé D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996;98:382–8PubMedCrossRef

96.

Wheatley LM, Wood R, Nadeau K, Liu A, Zoratti E, Bacharier L et al. Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy — An NIAID/AHRQ Workshop. J Allergy Clin Immunol 2019;143:1711–26PubMedCrossRef

97.

Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338–45PubMedCrossRef

98.

Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717–25.e5PubMedCrossRef

99.

Nelson H, Blaiss M, Nolte H, Würtz SØ, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013;68:252–5PubMedCrossRef

100.

Klimek L. AeDA/DGAKI informieren. Wirtschaftlichkeitsprüfung für SIT Lösungen. Aufgepasst! Hier wird oft falsch gerechnet. Allergo J 2015;24:88CrossRef

101.

Baiardini I, Puggioni F, Menoni S, Boot JD, Diamant Z, Braido F et al. Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respir Med 2013;107:361–7PubMedCrossRef

102.

Nam YH, Lee SK. Physician’s recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy. Patient Prefer Adherence 2017;11:381–7PubMedPubMedCentralCrossRef

103.

Chivato T, Álvarez-Calderón P, Panizo C, Abengozar R, Alías C, Al-Baech A et al. Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain. Clin Mol Allergy 2017;15:1PubMedPubMedCentralCrossRef

104.

Skoner DP, Blaiss MS, Dykewicz MS, Smith N, Leatherman B, Bielory L et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients’ experience with allergen immunotherapy. Allergy Asthma Proc 2014;35:219–26PubMedCrossRef

105.

Klimek L. Aufklärung vor Beginn einer allergenspezifischer Immuntherapie. AeDA empfiehlt Therapieinformationsblätter. Allergo J 2019;28:118CrossRef

106.

Bachert C, Gräfin von Strachwitz-Helmstatt K. Zur Diskussion gestellt: Der Arzt und die Spezifische Immuntherapie im Spannungsfeld von Leitlinie, Wirtschaftlichkeit und Medizinrecht. Allergologie 2016;39:381–8CrossRef

107.

Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy 2017;72:1825–48PubMedCrossRef

108.

Pitsios C, Dietis N. Ways to increase adherence to allergen immunotherapy. Curr Med Res Opin 2019;35:1027–31PubMedCrossRef

109.

Bender BG, Lockey RF. Solving the Problem of Nonadherence to Immunotherapy. Immunol Allergy Clin North Am 2016;36:205–13PubMedCrossRef

110.

Kuehl BL, Abdulnour S, O’Dell M, Kyle TK. Understanding the role of the healthcare professional in patient self-management of allergic rhinitis. SAGE Open Med 2015;3:2050312115595822PubMedPubMedCentralCrossRef

111.

Bosnic-Anticevich S, Costa E, Menditto E, Lourenço O, Novellino E, Bialek S et al. ARIA pharmacy 2018 „Allergic rhinitis care pathways for community pharmacy“: AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project. Allergy 2019;74:1219–36PubMed

112.

Bosnic-Anticevich S, Kritikos V, Carter V, Yan KY, Armour C, Ryan D et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia. J Asthma 2018;55:684–94PubMedCrossRef

113.

Finlay I, Egner W. Allergy — will we ever meet the unmet need? J R Soc Med 2010;103:430–1PubMedPubMedCentralCrossRef

114.

Jutel M, Papadopoulos NG, Gronlund H, Hoffman HJ, Bohle B, Hellings P et al. Recommendations for the allergy management in the primary care. Allergy 2014;69:708–18PubMedCrossRef

115.

Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T, Agache I et al.; ARIA and EPOS working groups. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis —A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy 2017;72:1297–305PubMedCrossRef

116.

Jutel M, Angier L, Palkonen S, Ryan D, Sheikh A, Smith H et al. Improving allergy management in the primary care network —a holistic approach. Allergy 2013;68:1362–9PubMedCrossRef

117.

Pinnock H, Thomas M, Tsiligianni I, Lisspers K, Østrem A, Ställberg B et al. The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. Prim Care Respir J 2010;19 Suppl 1:S1–20CrossRef

118.

Ewan PW, Durham SR. NHS allergy services in the UK: proposals to improve allergy care. Clin Med (Lond) 2002;2:122–7CrossRef

119.

Shehata Y, Ross M, Sheikh A. Undergraduate allergy teaching in a UK medical school: comparison of the described and delivered curriculum. Prim Care Respir J 2007;16:16–21PubMedPubMedCentralCrossRef

120.

Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E; EAACI, Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy 2006;61 Suppl 82:1–20PubMedCrossRef

121.

Landi M, Meglio P, Praitano E, Lombardi C, Passalacqua G, Canonica GW. The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clin Mol Allergy 2015;13:15PubMedPubMedCentralCrossRef

122.

Stokes JR, Casale TB. Allergy immunotherapy for primary care physicians. Am J Med 2006;119:820–3PubMedCrossRef

123.

Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H et al. GA(2)LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010;65:1525–30PubMedCrossRef

124.

Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012;67:709–11PubMedCrossRef

125.

Schmid-Grendelmeier P. Rekombinante Allergene. Routinediagnostik oder Wissenschaft? Hautarzt 2010;61:946–53PubMedCrossRef

126.

Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, Di Rienzo Businco A et al.; Italian Pediatric Allergy Network (I-PAN). The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol 2014;134:75–81PubMedCrossRef

127.

Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015;70:897–909PubMedCrossRef

128.

Global Strategy for Asthma Management and Prevention (2018 update). 2018; [URL: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf]

129.

Deutsches Institut für Medizinische Dokumentation und Information. Summary of product characteristics: Acarizax 12 SQ-HDM oral lyophilisate. 2016; [URL: https://portal.dimdi.de/amispb/doc/pei/Web/2613318-spcen-20150801.pdf]

130.

Amaral R, Fonseca JA, Jacinto T, Pereira AM, Malinovschi A, Janson C et al. Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007-2012. Clin Transl Allergy 2018;8:13PubMedPubMedCentralCrossRef

131.

Lu Z, Chen L, Xu S, Bao Q, Ma Y, Guo L et al. Allergic disorders and risk of depression: A systematic review and meta-analysis of 51 large-scale studies. Ann Allergy Asthma Immunol 2018;120:310–17.e2PubMedCrossRef

132.

Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T et al. S2k guideline on diagnosis and treatment of atopic dermatitis — short version. Allergo J Int 2016;25:82–95PubMedPubMedCentralCrossRef

133.

Worm M, Reese I, Ballmer-Weber B, Beyer K, Bischoff SC, Classen M et al. Guidelines on the management of IgE-mediated food allergies: S2k-Guidelines of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Medical Association of Allergologists (AeDA), the German Professional Association of Pediatricians (BVKJ), the German Allergy and Asthma Association (DAAB), German Dermatological Society (DDG), the German Society for Nutrition (DGE), the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS), the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery, the German Society for Pediatric and Adolescent Medicine (DGKJ), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Society for Pneumology (DGP), the German Society for Pediatric Gastroenterology and Nutrition (GPGE), German Contact Allergy Group (DKG), the Austrian Society for Allergology and Immunology (Æ-GAI), German Professional Association of Nutritional Sciences (VDOE) and the Association of the Scientific Medical Societies Germany (AWMF). Allergo J Int 2015;24:256–93PubMedPubMedCentralCrossRef

134.

Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy 2018;73:2352–63PubMedCrossRef

135.

Penagos M, Eifan AO, Durham SR, Scadding GW. Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. Curr Treat Options Allergy 2018;5:275–90PubMedPubMedCentralCrossRef

136.

Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018;141:529–38.e13PubMedCrossRef

137.

Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251–6PubMedCrossRef

138.

Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatric Allergy Immunol 2016;28:18–29CrossRef

139.

Bożek A, Kołodziejczyk K, Kozłowska R, Canonica GW. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial. Clin Transl Allergy 2017;7:43PubMedPubMedCentralCrossRef

140.

Bożek A, Kolodziejczyk K, Warkocka-Szoltysek B, Jarzab J. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Am J Rhinol Allergy 2014;28:423–7PubMedCrossRef

Titel: ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem
verfasst von: Ludger Klimek
Claus Bachert
Oliver Pfaar
Sven Becker
Thomas Bieber
Randolf Brehler
Roland Buhl
Ingrid Casper
Adam Chaker
Wolfgang Czech
Jörg Fischer
Thomas Fuchs
Michael Gerstlauer
Karl Hörmann
Thilo Jakob
Kirsten Jung
Matthias V. Kopp
Vera Mahler
Hans Merk
Norbert Mülleneisen
Katja Nemat
Uta Rabe
Johannes Ring
Joachim Saloga
Wolfgang Schlenter
Carsten Schmidt-Weber
Holger Seyfarth
Annette Sperl
Thomas Spindler
Petra Staubach
Sebastian Strieth
Regina Treudler
Christian Vogelberg
Andrea Wallrafen
Wolfgang Wehrmann
Holger Wrede
Torsten Zuberbier
Anna Bedbrook
Giorgio W. Canonica
Victoria Cardona
Thomas B. Casale
Wienczylawa Czarlewski
Wytske J. Fokkens
Eckard Hamelmann
Peter W. Hellings
Marek Jutel
Désirée Larenas-Linnemann
Joaquim Mullol
Nikolaos G. Papadopoulos
Sanna Toppila-Salmi
Thomas Werfel
Prof. Dr. Jean Bousquet
Publikationsdatum: 04.11.2019
Verlag: Springer Medizin
Schlagwörter: Asthma bronchiale
Pflege
Allergologie in der HNO-Heilkunde
Allergische Rhinitis
Allergenspezifische Immuntherapie
Allergenspezifische Immuntherapie
Histamin-H1-Rezeptorantagonisten
Erschienen in: Allergo Journal / Ausgabe 7/2019
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI: https://doi.org/10.1007/s15007-019-1938-2

Neu im Fachgebiet HNO

15.04.2024 | Hörsturz | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem

Zusammenfassung

Hintergrund

Methoden

Ergebnisse

Diskussion

Neu im Fachgebiet HNO

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Hundehalter mit Luftnot: War es die Katzenminze?

Update HNO

Springer Medizin

Zusammenfassung

Hintergrund

Methoden

Ergebnisse

Diskussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Adhärenz bei SCIT und SLIT als Schlüsselfaktor einer SIT

Hohe IgE-Spiegel schützen vor Krebs

Atopic eczema score of emotional consequences — a questionnaire to assess emotional consequences of atopic eczema

Antikörpertherapie bei atopischen Erkrankungen

Primärprävention von Allergien bei Kindern

14. Deutscher Allergiekongress — ein Rückblick in Bildern

Neu im Fachgebiet HNO

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Hundehalter mit Luftnot: War es die Katzenminze?

Update HNO